Loading...

PE anti-mouse CD206 (MMR) Antibody

Pricing & Availability
Clone
C068C2 (See other available formats)
Regulatory Status
RUO
Other Names
MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
C068C2_PE_1_082911
Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) APC, and then intracellularly stained with CD206 (clone C068C2) PE (top) or rat IgG2a, κ PE isotype control (bottom).
  • C068C2_PE_1_082911
    Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) APC, and then intracellularly stained with CD206 (clone C068C2) PE (top) or rat IgG2a, κ PE isotype control (bottom).
  • C068C2_PE_2_082911
Compare all formats See PE spectral data
Cat # Size Price Save
141705 25 µg ¥28,380
141706 100 µg ¥65,780
Description

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant mouse CD206 (MMR)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume.  It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.

Application References

(PubMed link indicates BioLegend citation)
  1. Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed
  2. Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed
  3. Yang X, et al. 2015. PNAS. 112:2900. PubMed
  4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Cui J, et al. 2021. J Cell Mol Med. 25:5586. PubMed
  2. Zhang B, et al. 2022. Front Med (Lausanne). 8:796743. PubMed
  3. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  4. Zhang Z, et al. 2022. Front Pharmacol. 13:906625. PubMed
  5. Yu L, et al. 2021. Cell Biol Int. 45:2452. PubMed
  6. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  7. Silveira DB, et al. 2022. Cell Biochem Funct. 40:163. PubMed
  8. Liang X, et al. 2022. Cancer Commun (Lond). 42:205. PubMed
  9. Lee R, et al. 2022. Cancer Discov. 12:1702. PubMed
  10. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  11. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  12. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  13. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  14. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  15. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  16. Li J, et al. 2023. Front Immunol. 13:945234. PubMed
  17. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  18. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  19. Li Y, et al. 2023. Cell Death Dis. 14:28. PubMed
  20. Zhang L, et al. 2023. J Inflamm Res. 16:109. PubMed
  21. Fan R, et al. 2023. J Immunother Cancer. 11: . PubMed
  22. Chun J, et al. 2023. Cancers (Basel). 15: . PubMed
  23. Li S, et al. 2023. Exp Mol Med. 55:457. PubMed
  24. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  25. Lundahl MLE, et al. 2022. Elife. 11:. PubMed
  26. Adzika GK, et al. 2023. Front Immunol. 14:1124649. PubMed
  27. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  28. Garabuczi É, et al. 2023. Front Immunol. 14:1139204. PubMed
  29. Chung JY, et al. 2023. Nat Commun. 14:1794. PubMed
  30. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  31. Pan C, et al. 2023. Front Bioeng Biotechnol. 11:1129187. PubMed
  32. Levra Levron C, et al. 2023. Nat Cell Biol. 25:740. PubMed
  33. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  34. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  35. Salemme V, et al. 2023. Nat Commun. 14:2350. PubMed
  36. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  37. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  38. Feng Y, et al. 2018. J Am Soc Nephrol. 29:182. PubMed
  39. Seo JB, et al. 2019. Nat Metab. 1:86. PubMed
  40. Ying W, et al. 2019. Cell Metab. 29:457. PubMed
  41. Sun H, et al. 2019. Mol Hum Reprod. 25:05:00. PubMed
  42. Xiong Y, et al. 2020. J Nanobiotechnology. 18:66. PubMed
  43. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
  44. Hu S, et al. 2018. Front Immunol. 9:01. PubMed
  45. Ying W et al. 2017. Cell. 171(2):372-384 . PubMed
  46. Nomura M, et al. 2016. Nat Immunol. 17:216-217. PubMed
  47. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  48. Zheng W, et al. 2021. Wellcome Open Research. 6:52. PubMed
  49. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  50. Dong L, et al. 2021. Cancer Cell. . PubMed
  51. Sadek J, et al. 2021. EMBO Mol Med. 13:e13591. PubMed
  52. Li Q, et al. 2021. Front Immunol. 12:707784. PubMed
  53. Clarke F,et al. 2017. PLoS One. 10.1371/journal.pone.0186625. PubMed
  54. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  55. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  56. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  57. De Vlaeminck Y, et al. 2020. Cancers (Basel). 12:. PubMed
  58. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  59. Krukowski K, et al. 2021. Sci Adv. 7:eabg6702. PubMed
  60. Pajarinen J, et al. 2021. J Biomed Mater Res A. 109:1512. PubMed
  61. Shao H, et al. 2012. J Biol Chem. 287:35860. PubMed
  62. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  63. Tang TT, et al. 2020. Sci Adv. 6:eaaz0748. PubMed
  64. Zhang J, et al. 2021. J Leukoc Biol. 110:485. PubMed
  65. Tanner L, et al. 2022. Front Pharmacol. 13:899469. PubMed
  66. Hou H, et al. 2021. Front Cell Dev Biol. 9:737003. PubMed
  67. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  68. Jia X, et al. 2021. Front Cell Dev Biol. 9:685522. PubMed
  69. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  70. El–Achkar GA, et al. 2019. PLoS One. 14:e0216405. PubMed
  71. McKee AM, et al. 2021. iScience. 24:103012. PubMed
  72. Zhang Y, et al. 2022. Nat Commun. 13:4553. PubMed
  73. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  74. Giri J, et al. 2020. Cell Rep. 30:1923. PubMed
  75. Dan H, et al. 2020. Mol Oncol. 14:795. PubMed
  76. Kim JS, et al. 2020. Int J Oncol. 56:1405. PubMed
  77. Martins L, et al. 2020. Stem Cell Res Ther. 0.786805556. PubMed
  78. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  79. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  80. Jiao Y, et al. 2021. Crit Care. 25:356. PubMed
  81. Farini A, et al. 2020. Front Physiol. 0.738194444. PubMed
  82. An W et al. 2019. British journal of pharmacology. 176(5):699-710 . PubMed
  83. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  84. Lu X, et al. 2020. Sci Transl Med. 12:. PubMed
  85. Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed
  86. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  87. Toubal A, et al. 2020. Nat Commun. 3755:11. PubMed
  88. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  89. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  90. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  91. Golden TN, et al. 2022. Front Pharmacol. 12:761496. PubMed
  92. Cai C, et al. 2021. Sci Rep. 11:13386. PubMed
  93. Lee DH, et al. 2019. PLoS One. 14:e0215727. PubMed
  94. Yu Y, et al. 2018. Mol Med Rep. 17:8212. PubMed
  95. Miura I, et al. 2021. Physiol Rep. 9:e14859. PubMed
  96. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  97. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  98. Ruiz de Azua I, et al. 2017. J Clin Invest. 127:4148. PubMed
  99. Shu Y, et al. 2020. Immunology. 160:345. PubMed
  100. Ying W, et al. 2016. Sci Rep. 6:20176. PubMed
  101. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  102. Sztwiertnia I, et al. 2020. PLoS One. 15:e0233789. PubMed
  103. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  104. Chu SY, et al. 2019. Nat Commun. 10:1524. PubMed
  105. Lu X, et al. 2012. Arterioscler Thromb Vasc Biol. 32:2358. PubMed
  106. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  107. Yang C, et al. 2022. Nat Commun. 13:4866. PubMed
  108. Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed
  109. Lowe PP, et al. 2020. J Neuroinflammation. 0.913888889. PubMed
  110. Zhou K, et al. 2016. J Cereb Blood Flow Metab. 10.1177/0271678X16648712. PubMed
  111. Deng W, et al. 2015. Clin Immunol. . PubMed
  112. Anderson-Baucum E, et al. 2021. Cell Metab. 33:1883. PubMed
  113. Stevenson ER, et al. 2022. J Pharmacol Exp Ther. 382:356. PubMed
  114. Wang X, et al. 2022. J Biol Chem. 298:101561. PubMed
  115. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  116. Asterholm I, et al. 2012. J Lipid Res. 53: 1254. PubMed
  117. Stridh L, et al. 2013. J Neurosci. 33:12401. PubMed
  118. Budai Z, et al. 2021. Cells. 10:. PubMed
  119. Zhu Q, et al. 2022. Atherosclerosis. 357:41. PubMed
  120. Long L, et al. 2018. Bio Protoc. 8:e2815. PubMed
  121. Li C, et al. 2019. JCI Insight. 5. PubMed
  122. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  123. Di Lorenzo A, et al. 2022. Oncoimmunology. 11:2086752. PubMed
  124. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  125. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  126. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  127. Krukowski K, et al. 2018. Sci Rep. 8:7857. PubMed
  128. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  129. Liu C, et al. 2022. Cell Death Discov. 8:269. PubMed
  130. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  131. Ukah T, et al. 2017. J Immunol. 10.4049/jimmunol.1700410. PubMed
  132. Roediger B et al. 2018. Cell. 175(2):530-543 . PubMed
  133. Budhu S, et al. 2021. Cell Reports. 34(2):108620. PubMed
  134. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  135. Browne A, et al. 2015. Cancer Res . 75: 2811 - 2821. PubMed
  136. Moreno M et al. 2014. The Journal of Neuroscience. 34(24):8175-85 . PubMed
  137. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  138. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  139. Zhang J, et al. 2020. J Cell Mol Med. 24:4547. PubMed
  140. Al-Zaeed N, et al. 2021. Cell Death Dis. 12:611. PubMed
  141. Golabek A, et al. 2021. Exp Ther Med. 21:482. PubMed
  142. Yeini E, et al. 2021. Nat Commun. 12:1912. PubMed
  143. Xu GY, et al. 2022. Small. 18:e2107838. PubMed
  144. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  145. Li B et al. 2019. Cell reports. 26(10):2720-2737 . PubMed
  146. Morioka S, et al. 2018. Nature. 563:714. PubMed
  147. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
  148. Yuan Y, et al. 2019. Clin Sci (Lond). 133:1759. PubMed
  149. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  150. Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed
  151. Cai T, et al. 2022. Front Immunol. 13:1009932. PubMed
  152. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  153. Guo S, et al. 2021. Chronic Dis Transl Med. 7:254. PubMed
  154. Chuan Li et al. 2017. Endocrinology. 158(9):2837-2847 . PubMed
  155. Wen HJ, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:p173. PubMed
  156. Yuan M, et al. 2017. Hum Reprod. 32:94. PubMed
  157. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  158. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_10895754 (BioLegend Cat. No. 141705)
AB_10895754 (BioLegend Cat. No. 141706)

Antigen Details

Structure
Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution

Macrophages, dendritic cells, Langerhans cells, liver endothelial cells

Function
Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor
Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type
Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References

1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501.
2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469.
3. Burgdorf S, et al. 2006. J. Immunol. 176:6770.
4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.

Gene ID
17533 View all products for this Gene ID
UniProt
View information about CD206 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Why is mouse CD206 stained intracellularly and not via surface staining?

Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.

Go To Top Version: 3    Revision Date: 04/04/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account